sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group, Inc. Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 concerning its interests in Avadel Pharmaceuticals PLC. As of January 9, 2026, Vanguard held 6.03% in ordinary shares, totaling 5,871,186 shares. The disclosure aligns with Rule 8.3 of the Irish Takeover Panel Act of 1997.
The document highlights Vanguard's recent transactions involving US$0.01 ordinary shares of Avadel Pharmaceuticals. The group purchased 1,923 shares and sold 92 shares, both at a price of 21.50 USD per share.
No cash-settled or stock-settled derivative positions were reported. Additionally, there are no relevant indemnity, option, or voting rights agreements related to Avadel shares.
The form emphasizes transparency in compliance with takeover rules while maintaining neutrality in its investments.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.